Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 6/2021

27.05.2021 | Chronisch-entzündliche Darmerkrankungen | CME

Update: enteropathische Spondyloarthritis

verfasst von: Prof. Dr. med. Elisabeth Märker-Hermann

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Spondyloarthritiden (SpA) gehören zu den häufigsten extraintestinalen Manifestationen der chronisch entzündlichen Darmerkrankungen (CED). Auch bestimmte arthritogene Enterobakterien können als Folgeerkrankung der Gastroenteritis eine reaktive enteropathische SpA auslösen. Die Erforschung der „Darm-Synovium-Achse“ unter genetischen, immunologischen, klinischen und therapeutischen Gesichtspunkten hat die enteropathische SpA zu einer Modellerkrankung der SpAs gemacht. Ähnliches gilt für die Erforschung der CED, da die subklinischen Darmentzündungen bei Patienten mit SpA dazu beigetragen haben, die Mukosa-assoziierten frühen Immunphänomene des Morbus Crohn (CD) besser zu verstehen. Dieser Beitrag stellt neben den pathognomonischen klinischen Bildern, der Diagnostik und Differenzialdiagnostik die aktuellen pathogenetischen Modelle der enteropathischen SpAs vor. Aus dem Wissen um pathogenetische Zusammenhänge ergeben sich konkrete Empfehlungen zur Therapie, wobei individuell nach der zugrunde liegenden Darmerkrankung, nach der entzündlichen intestinalen oder rheumatischen Aktivität und nach dem rheumatologischen Befallsmuster unterschieden wird.
Literatur
1.
Zurück zum Zitat Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20:451PubMedCrossRef Rudwaleit M, Baeten D (2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 20:451PubMedCrossRef
2.
Zurück zum Zitat Shivashankar R, Loftus EV Jr, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR (2012) Matteson EL Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. J Rheumatol 39:2148–2152PubMedPubMedCentralCrossRef Shivashankar R, Loftus EV Jr, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR (2012) Matteson EL Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. J Rheumatol 39:2148–2152PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Shivashankar R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Matteson EL (2013) Incidence of Spondyloarthropathy in patients with ulcerative colitis: a population-based study. J Rheumatol 40:1153–1157PubMedCrossRef Shivashankar R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Matteson EL (2013) Incidence of Spondyloarthropathy in patients with ulcerative colitis: a population-based study. J Rheumatol 40:1153–1157PubMedCrossRef
4.
Zurück zum Zitat Vavricka SR, Brun L, Ballabeni P et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106:110–119PubMedCrossRef Vavricka SR, Brun L, Ballabeni P et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106:110–119PubMedCrossRef
5.
Zurück zum Zitat Karreman MC, Luime JJ, Hazes JM, Weel AE (2017) The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:631–642PubMed Karreman MC, Luime JJ, Hazes JM, Weel AE (2017) The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 11:631–642PubMed
6.
Zurück zum Zitat Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP (2000) Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118:274–278PubMedCrossRef Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP (2000) Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118:274–278PubMedCrossRef
7.
Zurück zum Zitat Peeters H, Vander Cruyssen B, Laukens D et al (2004) Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 63:1131–1134PubMedPubMedCentralCrossRef Peeters H, Vander Cruyssen B, Laukens D et al (2004) Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 63:1131–1134PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Zeitz J, Vavricka SR (2013) Therapie der extraintestinalen CED-Manifestationen : Eine schwierige Herausforderung. Gastroenterologe 8:217–225CrossRef Zeitz J, Vavricka SR (2013) Therapie der extraintestinalen CED-Manifestationen : Eine schwierige Herausforderung. Gastroenterologe 8:217–225CrossRef
9.
Zurück zum Zitat Travis S (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The south west gastroenterology group. Eur J Gastroenterol Hepatol 9:15–720CrossRef Travis S (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The south west gastroenterology group. Eur J Gastroenterol Hepatol 9:15–720CrossRef
10.
Zurück zum Zitat Märker-Hermann E (2020) Reaktive Arthritis – eine vergessene Erkrankung? Dtsch Med Wochenschr 145:1786–1790PubMedCrossRef Märker-Hermann E (2020) Reaktive Arthritis – eine vergessene Erkrankung? Dtsch Med Wochenschr 145:1786–1790PubMedCrossRef
11.
Zurück zum Zitat Ajene AN, Fischer Walker CL, Black RE (2013) Enteric pathogens and reactive arthritis: a systematic review of campylobacter, salmonella and shigella-associated reactive arthritis. J Health Popul Nutr 31:299PubMedPubMedCentralCrossRef Ajene AN, Fischer Walker CL, Black RE (2013) Enteric pathogens and reactive arthritis: a systematic review of campylobacter, salmonella and shigella-associated reactive arthritis. J Health Popul Nutr 31:299PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Vasala M, Hallanvuo S, Ruuska P et al (2014) High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused by contaminated grated carrots. Ann Rheum Dis 73:1793–1796PubMedCrossRef Vasala M, Hallanvuo S, Ruuska P et al (2014) High frequency of reactive arthritis in adults after Yersinia pseudotuberculosis O:1 outbreak caused by contaminated grated carrots. Ann Rheum Dis 73:1793–1796PubMedCrossRef
13.
Zurück zum Zitat Tuompo R, Lääveri T, Hannu T et al (2020) Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic escherichia coli (DEC). Ann Rheum Dis 79:605–611PubMedCrossRef Tuompo R, Lääveri T, Hannu T et al (2020) Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic escherichia coli (DEC). Ann Rheum Dis 79:605–611PubMedCrossRef
14.
Zurück zum Zitat Mielants H, Veys EM, Cuvelier C et al (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed Mielants H, Veys EM, Cuvelier C et al (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed
15.
Zurück zum Zitat Mielants H, Veys EM, Cuvelier C, De Vos M (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10:147–164PubMedCrossRef Mielants H, Veys EM, Cuvelier C, De Vos M (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10:147–164PubMedCrossRef
16.
Zurück zum Zitat Van Praet L, Van den Bosch FE, Jacques P et al (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417PubMedCrossRef Van Praet L, Van den Bosch FE, Jacques P et al (2013) Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 72:414–417PubMedCrossRef
17.
Zurück zum Zitat Klingberg E, Strid H, Ståhl A et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21PubMedPubMedCentralCrossRef Klingberg E, Strid H, Ståhl A et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Rudwaleit M, van der Heijde D, Landewe R et al (2011) The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31PubMedCrossRef Rudwaleit M, van der Heijde D, Landewe R et al (2011) The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31PubMedCrossRef
19.
Zurück zum Zitat Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef
20.
Zurück zum Zitat Chan J, Sari I, Salonen D, Silverberg MS et al (2018) Prevalence of sacroiliitis in inflammatory bowel disease using a standardized CT scoring system. Arthritis Care Res (Hoboken) 70:807–810CrossRef Chan J, Sari I, Salonen D, Silverberg MS et al (2018) Prevalence of sacroiliitis in inflammatory bowel disease using a standardized CT scoring system. Arthritis Care Res (Hoboken) 70:807–810CrossRef
21.
Zurück zum Zitat Kiltz U, Braun J, DGRh et al (2019) Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019. Z Rheumatol 78:3–64PubMedCrossRef Kiltz U, Braun J, DGRh et al (2019) Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019. Z Rheumatol 78:3–64PubMedCrossRef
22.
Zurück zum Zitat Leclerc-Jacob S, Lux G, Rat AC et al (2014) The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 39:957–962PubMedCrossRef Leclerc-Jacob S, Lux G, Rat AC et al (2014) The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 39:957–962PubMedCrossRef
23.
Zurück zum Zitat de Miguel E, Cobo T, Muñoz-Fernández S et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68:169–174PubMedCrossRef de Miguel E, Cobo T, Muñoz-Fernández S et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68:169–174PubMedCrossRef
24.
Zurück zum Zitat Silverberg MS, Mirea L, Bull SB et al (2003) A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 9:1–9PubMedCrossRef Silverberg MS, Mirea L, Bull SB et al (2003) A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 9:1–9PubMedCrossRef
25.
Zurück zum Zitat Ossum AM, Palm Ø, Lunder AK et al (2018) Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis 12:96–104PubMedCrossRef Ossum AM, Palm Ø, Lunder AK et al (2018) Ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis 12:96–104PubMedCrossRef
26.
Zurück zum Zitat De Vos M, Hindryckx P, Laukens D (2011) Novel development in extraintestinal manifestations and spondylarthropathy. Best Pract Res Clin Gastroenterol 25(1):S19–S26PubMedCrossRef De Vos M, Hindryckx P, Laukens D (2011) Novel development in extraintestinal manifestations and spondylarthropathy. Best Pract Res Clin Gastroenterol 25(1):S19–S26PubMedCrossRef
27.
Zurück zum Zitat van der Paardt M, Crusius JBA, de Koning MHMT et al (2003) CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 4:77–78PubMedCrossRef van der Paardt M, Crusius JBA, de Koning MHMT et al (2003) CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 4:77–78PubMedCrossRef
28.
Zurück zum Zitat D’Amato M, Sorrentino R, Pettersson S (2014) The Crohn’s associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol 41:187 D’Amato M, Sorrentino R, Pettersson S (2014) The Crohn’s associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. J Rheumatol 41:187
29.
Zurück zum Zitat Laukens D, Peeters H, Marichal D et al (2005) CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 64:930–935PubMedCrossRef Laukens D, Peeters H, Marichal D et al (2005) CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn’s disease. Ann Rheum Dis 64:930–935PubMedCrossRef
30.
Zurück zum Zitat Danoy P, Pryce K, Hadler J et al (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet 6:e1001195PubMedPubMedCentralCrossRef Danoy P, Pryce K, Hadler J et al (2010) Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn’s disease. PLoS Genet 6:e1001195PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Laukens D, Georges M, Libioulle C et al (2010) Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. PLoS One 5:e13795PubMedPubMedCentralCrossRef Laukens D, Georges M, Libioulle C et al (2010) Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. PLoS One 5:e13795PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Pointon JJ, Harvey D, Karaderi T et al (2010) Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene. Genes Immun 11:490–496PubMedPubMedCentralCrossRef Pointon JJ, Harvey D, Karaderi T et al (2010) Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene. Genes Immun 11:490–496PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463PubMedPubMedCentralCrossRef Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461–1463PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat The Australo-Anglo-American Spondyloarthritis Consortium (TASC) (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42:123–127CrossRef The Australo-Anglo-American Spondyloarthritis Consortium (TASC) (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42:123–127CrossRef
36.
Zurück zum Zitat Leppkes M, Roulis M, Neurath MF et al (2014) Pleiotropic functions of TNF‑α in the regulation of the intestinal epithelial response to inflammation. Int Immunol 26:509–515PubMedCrossRef Leppkes M, Roulis M, Neurath MF et al (2014) Pleiotropic functions of TNF‑α in the regulation of the intestinal epithelial response to inflammation. Int Immunol 26:509–515PubMedCrossRef
37.
Zurück zum Zitat Mei Y, Pan F, Gao J et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273PubMedCrossRef Mei Y, Pan F, Gao J et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269–273PubMedCrossRef
38.
Zurück zum Zitat Appel H, Maier R, Wu P et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95PubMedPubMedCentralCrossRef Appel H, Maier R, Wu P et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Ciccia F, Bombardieri M, Principato A et al (2009) Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60:955–965PubMedCrossRef Ciccia F, Bombardieri M, Principato A et al (2009) Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 60:955–965PubMedCrossRef
40.
Zurück zum Zitat Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRef Sherlock JP, Joyce-Shaikh B, Turner SP et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18:1069–1076PubMedCrossRef
41.
Zurück zum Zitat Benham H, Rehaume LM, Hasnain SZ et al (2014) Interleukin-23 mediates the intestinal response to microbial β‑1,3‑glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 66:1755–1767PubMedCrossRef Benham H, Rehaume LM, Hasnain SZ et al (2014) Interleukin-23 mediates the intestinal response to microbial β‑1,3‑glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 66:1755–1767PubMedCrossRef
42.
Zurück zum Zitat Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364PubMedCrossRef Taurog JD, Richardson JA, Croft JT et al (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359–2364PubMedCrossRef
43.
Zurück zum Zitat Breban M, Tap J, Leboime A et al (2017) Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 76:1614–1622PubMedCrossRef Breban M, Tap J, Leboime A et al (2017) Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis 76:1614–1622PubMedCrossRef
44.
Zurück zum Zitat Tito RY, Cypers H, Joossens M et al (2017) Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 69:114–121PubMedCrossRef Tito RY, Cypers H, Joossens M et al (2017) Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 69:114–121PubMedCrossRef
45.
Zurück zum Zitat Gracey E, Qaiyum Z, Almaghlouth I et al (2016) IL‑7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 75:2124–2132PubMedCrossRef Gracey E, Qaiyum Z, Almaghlouth I et al (2016) IL‑7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 75:2124–2132PubMedCrossRef
46.
Zurück zum Zitat Qaiyum Z, Gracey E, Yao Y, Inman RD (2019) Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis 78:1566PubMedCrossRef Qaiyum Z, Gracey E, Yao Y, Inman RD (2019) Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis 78:1566PubMedCrossRef
47.
Zurück zum Zitat May E, Märker-Hermann E, Wittig BM et al (2000) Identical T‑cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 119:1745–1755PubMedCrossRef May E, Märker-Hermann E, Wittig BM et al (2000) Identical T‑cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology 119:1745–1755PubMedCrossRef
48.
Zurück zum Zitat Severs M, van Erp SJ, van der Valk ME, Dutch Initiative on Crohn and Colitis et al (2016) Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:455–461PubMedCrossRef Severs M, van Erp SJ, van der Valk ME, Dutch Initiative on Crohn and Colitis et al (2016) Smoking is associated with extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 10:455–461PubMedCrossRef
49.
Zurück zum Zitat Preiß JC, Bokemeyer B, Buhr HJ et al (2014) Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014. AWMF-Registrierungsnummer: 021-004. Z Gastroenterol 52:1431–1484PubMedCrossRef Preiß JC, Bokemeyer B, Buhr HJ et al (2014) Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014. AWMF-Registrierungsnummer: 021-004. Z Gastroenterol 52:1431–1484PubMedCrossRef
50.
Zurück zum Zitat Kucharzik T, Dignass AU, Atreya R et al (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa—Living Guideline August 2020—AWMF-Registriernummer: 021-009. Z Gastroenterol 58:e241–e345PubMedCrossRef Kucharzik T, Dignass AU, Atreya R et al (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa—Living Guideline August 2020—AWMF-Registriernummer: 021-009. Z Gastroenterol 58:e241–e345PubMedCrossRef
51.
Zurück zum Zitat Tadbiri S, Peyrin-Biroulet L, Serrero M, Getaid Observ-IBD study group et al (2018) Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the Observ-IBD cohort. Aliment Pharmacol Ther 47:485–493PubMedCrossRef Tadbiri S, Peyrin-Biroulet L, Serrero M, Getaid Observ-IBD study group et al (2018) Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the Observ-IBD cohort. Aliment Pharmacol Ther 47:485–493PubMedCrossRef
52.
Zurück zum Zitat Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 42:2325–2329PubMedCrossRef Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 42:2325–2329PubMedCrossRef
53.
Zurück zum Zitat Van den Bosch F, Kruithof E, De Vos M et al (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821–1822PubMedCrossRef Van den Bosch F, Kruithof E, De Vos M et al (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356:1821–1822PubMedCrossRef
54.
Zurück zum Zitat Generini S, Giacomelli R, Fedi R et al (2004) Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63:1664–1669PubMedPubMedCentralCrossRef Generini S, Giacomelli R, Fedi R et al (2004) Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63:1664–1669PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Luchetti MM, Benfaremo D, Ciccia F et al (2017) Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. World J Gastroenterol 23:7139–7149PubMedPubMedCentralCrossRef Luchetti MM, Benfaremo D, Ciccia F et al (2017) Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. World J Gastroenterol 23:7139–7149PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRef Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRef
57.
Zurück zum Zitat Marzo-Ortega H, McGonagle D, O’Connor P et al (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76PubMedPubMedCentralCrossRef Marzo-Ortega H, McGonagle D, O’Connor P et al (2003) Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis 62:74–76PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367:1519–1528PubMedCrossRef Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367:1519–1528PubMedCrossRef
59.
Zurück zum Zitat Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMedCrossRef Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381:1201–1214PubMedCrossRef
60.
Zurück zum Zitat Deodhar A, Gensler LS, Sieper J et al (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71:258–270PubMedCrossRef Deodhar A, Gensler LS, Sieper J et al (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71:258–270PubMedCrossRef
61.
Zurück zum Zitat Song X, Dai D, He X, Zhu S, Yao Y, Gao H, Wang J, Qu F, Qiu J, Wang H et al (2015) Growth factor FGF2 cooperates with Interleukin-17 to repair intestinal epithelial damage. Immunity 43:488–501PubMedCrossRef Song X, Dai D, He X, Zhu S, Yao Y, Gao H, Wang J, Qu F, Qiu J, Wang H et al (2015) Growth factor FGF2 cooperates with Interleukin-17 to repair intestinal epithelial damage. Immunity 43:488–501PubMedCrossRef
62.
Zurück zum Zitat Burisch J, Eigner W, Schreiber S et al (2020) Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS ONE 15(5):e233781PubMedPubMedCentralCrossRef Burisch J, Eigner W, Schreiber S et al (2020) Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS ONE 15(5):e233781PubMedPubMedCentralCrossRef
Metadaten
Titel
Update: enteropathische Spondyloarthritis
verfasst von
Prof. Dr. med. Elisabeth Märker-Hermann
Publikationsdatum
27.05.2021

Weitere Artikel der Ausgabe 6/2021

Zeitschrift für Rheumatologie 6/2021 Zur Ausgabe

Mitteilungen der DRL

Mitteilungen der DRL

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Klinische Studien kurzgefasst

Wenn schon rauchen, dann auch trinken?

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?